Hellman & Friedman’s PPD Shows PE Growth in Action

Pharmaceutical Product Development, which provides contract research services companies to pharma and biotech companies worldwide, has returned to the public markets. Its IPO, on Thursday, February 6, came eight-plus years after Hellman & Friedman and Carlyle completed its leveraged buyout of the company. The result? PPD’s IPO assigned it an initial enterprise value close to $14 billion, up from the $3.6 billion valuation at which it was valued in its December 2011 take-private transaction.

Read the full article: Hellman & Friedman’s PPD Shows PE Growth in Action //

Source: https://www.pehub.com/hellman-friedmans-ppd-shows-pe-growth-in-action-2

Scroll to Top